For patients in countries where advanced oncology infrastructure is limited, or where treatment costs are prohibitive, accessing that expertise has historically been a significant challenge. India's thoracic oncology programmes are changing that reality - and DivinHeal is the platform that makes accessing them straightforward.
Understanding Lung Cancer
Lung cancer is broadly divided into two main types:
Non-Small Cell Lung Cancer (NSCLC): Accounts for approximately 85% of all lung cancers. Includes adenocarcinoma (most common, often found in non-smokers, frequently harbouring targetable mutations), squamous cell carcinoma, and large cell carcinoma. Treatment approach depends heavily on stage and molecular profile.
Small Cell Lung Cancer (SCLC): Approximately 15% of lung cancers. Grows faster and spreads earlier than NSCLC. Highly sensitive to initial chemotherapy and radiation, but prone to relapse.
Staging - determining how far the cancer has spread - is critical. Early-stage (Stage I-II) lung cancer is treated primarily with surgery. Locally advanced (Stage III) disease is treated with combined chemotherapy and radiation. Metastatic (Stage IV) disease is managed with systemic therapy - targeted agents, immunotherapy, or chemotherapy depending on molecular profile.
Molecular Testing: The Foundation of Modern Lung Cancer Care
Before any systemic treatment decision is made, India's leading oncology centres perform comprehensive molecular profiling of the tumour. This includes testing for:
EGFR mutations (present in 30-50% of Asian patients with adenocarcinoma) - targetable with oral TKI drugs like osimertinib, erlotinib, gefitinib. ALK and ROS1 rearrangements - targetable with alectinib, crizotinib. KRAS G12C mutations - targetable with sotorasib. PD-L1 expression - predicts response to immunotherapy. BRAF, MET, RET, and NTRK alterations - each with specific targeted agents.
This precision oncology approach means that many lung cancer patients receive a targeted oral medication rather than traditional chemotherapy - with significantly better outcomes and tolerability.
Treatment Options in India
Surgery: For early-stage NSCLC, surgical removal of the tumour (lobectomy, segmentectomy, or pneumonectomy) offers the best chance of cure. Video-assisted thoracoscopic surgery (VATS) and robotic thoracic surgery allow lung resection through small chest incisions, dramatically reducing recovery time compared to open thoracotomy.
Radiation Therapy: SBRT (Stereotactic Body Radiation Therapy) delivers high-dose, precisely targeted radiation to early-stage tumours in patients who are not surgical candidates - achieving excellent local control rates. For locally advanced disease, concurrent chemoradiation is the standard approach.
Targeted Therapy: Oral medications that specifically block the molecular drivers of the cancer. India has access to the full range of targeted agents at significantly lower cost than in Western markets.
Immunotherapy: Checkpoint inhibitors (pembrolizumab, atezolizumab, nivolumab) activate the immune system against the cancer. Available in India at a fraction of US prices, either as monotherapy or combined with chemotherapy.
Chemotherapy: Platinum-based combination regimens remain the backbone of treatment for many patients, particularly SCLC and NSCLC without targetable mutations.
DivinHeal's Role in Your Lung Cancer Journey
DivinHeal begins with a review of your pathology reports, imaging, and molecular testing results. Within 24-48 hours, the medical team identifies the most appropriate oncology centre and specialist for your specific cancer type and stage, provides a detailed treatment plan and cost breakdown, and arranges your first consultation - via telemedicine or in person in India.
Time matters in lung cancer. DivinHeal moves quickly, because you need to.
FAQs
Q1. How soon can I start lung cancer treatment in India through DivinHeal?
DivinHeal prioritises cancer cases. Initial telemedicine consultation is typically arranged within 48-72 hours of submitting medical records. If travel to India is required, appointments are scheduled within 1-2 weeks of arrival. Treatment can usually begin within days of consultation.
Q2. Is molecular testing available in India for lung cancer?
Yes. India's leading oncology centres offer comprehensive next-generation sequencing (NGS) panels that test for all major targetable mutations simultaneously. If you have not had molecular testing done at home, it can be performed in India as part of your initial workup.
Q3. Can lung cancer be cured?
Early-stage (Stage I-II) lung cancer treated with surgery has 5-year survival rates of 60-90%. Even some Stage III patients achieve long-term remission with combined modality treatment. Stage IV disease is generally not curable, but targeted therapies and immunotherapy have transformed it into a manageable chronic condition for many patients, with some living 5 years or more.
Q4. What does lung cancer treatment cost in India compared to the US?
A full course of targeted therapy that costs $10,000-$15,000 per month in the US may cost $1,000-$3,000 per month in India for the same drug. VATS lobectomy costs $5,000-$8,000 in India versus $50,000-$80,000 in the US. DivinHeal provides itemised cost breakdowns for all treatment plans.
Q5. Does DivinHeal help with follow-up care after returning home?
Yes. DivinHeal coordinates remote follow-up with your treating oncologist in India via telemedicine. CT scans and blood tests can be performed locally and the results reviewed by the Indian team. Any changes in treatment can be discussed and implemented remotely for oral medications.